EUVIMEDEUVIMED entdecken
Crossref

Characterization of 223 infants with CFTR-related metabolic syndrome/Cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID) identified during the first three years of newborn screening via IRT-DNA-SEQ in New York State

Hossein Sadeghi, Denise M Kay, Elinor Langfelder-Schwind, Joan K DeCelie-Germana, Maria Berdella, Zafer N Soultan, Danielle M Goetz, Michele Caggana, Christopher N Fortner, Robert Giusti, Robert Kaslovsky, Colleen Stevens und 5 weitere

Journal of Cystic Fibrosis · 2025-03 · 24 (2) · 404-411

DOI: 10.1016/j.jcf.2024.10.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025-03. Verfasst von Hossein Sadeghi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Columbia University Irving Medical Center, NY USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Neonatal Screening, Cystic Fibrosis Transmembrane Conductance Regulator, Metabolic Syndrome. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Cystic Fibrosis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: New York State implemented CFTR gene sequencing into the Cystic Fibrosis newborn screening (CF NBS) algorithm on 12/1/2017 to reduce false positive screens. With addition of sequencing, infants with 2 CFTR variants but low or intermediate sweat chloride levels classified as CFTR-related metabolic syndrome/CF screen-positive, inconclusive diagnosis (CRMS/CFSPID) are identified at a higher frequency, posing challenges to clinicians and families. METHODS: Data from 375 screen-positive newborns between 12/1/2017 and 11/30/2020 were analyzed. We summarized 1-3 years of clinical follow-up for babies with CRMS/CFSPID following implementation of the IRT-DNA-SEQ algorithm. RESULTS: Among 375 newborns referred, 223 (59.5 %) were classified as CRMS/CFSPID. Overall, 195/223 (87.4 %) had a CF-causing/pathogenic/likely pathogenic CFTR variant and a variant of varying clinical consequence (VCC) or uncertain significance (VUS). The most common VCC or VUS was 5T-12TG [n = 90/223 (40 %)]. All initial and repeat sweat chloride test (SCT) values for this cohort were

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisNeonatal ScreeningCystic Fibrosis Transmembrane Conductance RegulatorMetabolic SyndromeHumansInfant, NewbornNew YorkMaleFemaleGenetic TestingSweatInfant

Stichwörter der Autor:innen

CF conversionCFTR sequencingCystic fibrosis screen positiveCystic fibrosis transmembrane conductance regulator-related metabolic syndrome…IRT-DNA-SEQ newborn screening algorithminconclusive diagnosis (CFSPID)sweat chloride trends

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorCFTR protein, human

Autor:innen und Institutionen

  • Columbia University Irving Medical Center, NY USA.
  • Newborn Screening Program, Division of Genetics, Wadsworth Center, New York State Department of Health, Albany, NY, USA.
  • Lenox Hill Hospital, Northwell Health System NY NY, USA.
  • Cohen Children's Medical Center, Northwell Health System, New Hyde Park, NY, USA.
  • Upstate Medical University, Syracuse, NY, USA.
  • University at Buffalo School of Medicine, Buffalo, NY, USA.

Förderung

  • Cystic Fibrosis Foundation

Zitieren

APA

Sadeghi, H., Kay, D. M., Langfelder-Schwind, E., DeCelie-Germana, J. K., Berdella, M., Soultan, Z. N., Goetz, D. M., Caggana, M., Fortner, C. N., Giusti, R., Kaslovsky, R., Stevens, C., Tavakoli, N., Voter, K., Welter, J. J., Kier, C., & New York State Cystic Fibrosis Newborn Screening Consortium (2025). Characterization of 223 infants with CFTR-related metabolic syndrome/Cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID) identified during the first three years of newborn screening via IRT-DNA-SEQ in New York State. Journal of Cystic Fibrosis, 24(2), 404-411. https://doi.org/10.1016/j.jcf.2024.10.015

Vancouver

Sadeghi H, Kay DM, Langfelder-Schwind E, DeCelie-Germana JK, Berdella M, Soultan ZN, et al. Characterization of 223 infants with CFTR-related metabolic syndrome/Cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID) identified during the first three years of newborn screening via IRT-DNA-SEQ in New York State. Journal of Cystic Fibrosis. 2025;24(2):404-411. doi:10.1016/j.jcf.2024.10.015

BibTeX
@article{Sadeghi2025,
  author = {Sadeghi, Hossein and Kay, Denise M and Langfelder-Schwind, Elinor and DeCelie-Germana, Joan K and Berdella, Maria and Soultan, Zafer N and Goetz, Danielle M and Caggana, Michele and Fortner, Christopher N and Giusti, Robert and Kaslovsky, Robert and Stevens, Colleen and Tavakoli, Norma and Voter, Karen and Welter, John J and Kier, Catherine and New York State Cystic Fibrosis Newborn Screening Consortium, New York State Cystic Fibrosis Newborn Screening Consortium},
  title = {Characterization of 223 infants with CFTR-related metabolic syndrome/Cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID) identified during the first three years of newborn screening via IRT-DNA-SEQ in New York State},
  journal = {Journal of Cystic Fibrosis},
  year = {2025},
  volume = {24},
  number = {2},
  pages = {404--411},
  doi = {10.1016/j.jcf.2024.10.015}
}
Kostenlos starten →